AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma drug Fasenra (benralizumab) in
https://www.nasdaq.com/articles/chmp-endorses-astrazenecas-fasenra-rare-autoimmune-disease